ERBB2 and neoplasm: Notably, in vivo studies using HER2-overexpressing USC xenograft models showed that T-DM1 markedly reduced tumor growth (p = 0.04), and mice treated with T-DM1 experienced significantly prolonged survival compared to those receiving trastuzumab alone or the saline control treatment (p ≤ 0.001) [132].